Brenntag


Q3 26: Price-driven sales beat, weak cash conversion

11/11/26 -"Brenntag’s Q3 sales beat consensus by 6.6%, supported by higher chemical prices and favourable FX. However, operating EBITDA was broadly in line with expectations, while EPS missed by 5%. Higher ..."

Pages
44
Language
English
Published on
11/11/26
You may also be interested by these reports :
11/11/26
Brenntag’s Q3 sales beat consensus by 6.6%, supported by higher chemical prices and favourable FX. However, operating EBITDA was broadly in line with ...

11/11/26
1Q26/27: All in all, a solid start – FY26/27E guidance confirmed

10/11/26
K+S’s Q3 2026 sales growth was driven by price and mix, not volume, as the Bethune shutdown hit volumes. De-icing refill demand lifted Industry+. ...

09/11/26
K+S (ADD; Germany) mines potash and magnesium products in Germany and at Bethune in Canada, with a salt business on the side. The shares trade as a ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO